The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-Preserved
Open accessAbstract
Aims: Heart failure is characterized by recurrent hospitalizations, but often only the first event is considered in clinical trial reports. In chronic diseases, such as heart failure, analysing all events gives a more complete picture of treatment benefit. We describe methods of analysing repeat hospitalizations, and illustrate their value in one major trial. Methods and results: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved study compared candesartan with placebo in 3023 patients with heart failure and preserved systolic function. The heart failure hospitalization rates were 12.5 and 8.9 per 100 patient-years in the placebo and candesartan groups, respectively. The repeat hospitalizations were analysed using the Andersen–Gill, Poisson, and negative binomial methods. Death was incorporated into analyses by treating it as an additional event. The win ratio method and a method that jointly models hospitalizations and mortality were also considered. Using repeat events gave larger treatment benefits than time to first event analysis. The negative binomial method for the composite of recurrent heart failure hospitalizations and cardiovascular death gave a rate ratio of 0.75 [95% confidence interval (CI) 0.62–0.91, P = 0.003], whereas the hazard ratio for time to first heart failure hospitalization or cardiovascular death was 0.86 (95% CI 0.74–1.00, P = 0.050). Conclusions: In patients with preserved EF, candesartan reduces the rate of admissions for worsening heart failure, to a greater extent than apparent from analysing only first hospitalizations. Recurrent events should be routinely incorporated into the analysis of future clinical trials in heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a pre-specified statistical method, we used the negative binomial regression model to calculate rates and rate ratios for total cardiovascular events, which accounts for the variability in each patient's risk of events (45-47).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Self-citationCox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
Self-citationMcMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Self-citationPfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citationGranger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14284-5 · Cited by 1,686
Self-citationSolomon, S. D., Zile, M. R., Pieske, B. M., Voors, A. A., Shah, A. M., Kraigher‐Krainer, E., Shi, V. C., Bransford, T. L., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,171
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
Self-citation2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Efficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159
2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,356
Self-citation
Metadata
- Authors
- Rogers, J. K., Pocock, S. J., McMurray, J. J. V., Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K., & Yusuf, S.
- Affiliations
- London School of Hygiene & Tropical Medicine (GB)
- University of Glasgow (GB)
- Duke University (US)
- AstraZeneca (United States) (US)
- Karolinska University Hospital (SE)
- Brigham and Women's Hospital (US)
- Imperial College London (GB)
- Hamilton Health Sciences (CA)
- Corresponding author
- Rogers, Jennifer K.
- ORCID
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-18
- Volume
- 16
- Issue
- 1
- Pages
- 33-40
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- PMC
- PMC4822681
- OpenAlex
- W1870916828
- Cited by
- 226
- References
- 26
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 23 · 2021: 28 · 2020: 11 · 2019: 20 · 2018: 21 · 2017: 26 · 2016: 23 · 2015: 13 · 2014: 8 · 2013: 2
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Heart Failure (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- AstraZeneca
- National Institute for Health and Care Research (PDF-2013-06-024)
- Medical Research Council (MC_EX_G0800814)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Keywords
- heart failure, recurrent hospitalization, heart failure with preserved ejection fraction, candesartan, Andersen-Gill model, negative binomial regression, Poisson regression, win ratio, treatment benefit, cardiovascular mortality
- MeSH terms
- Data Interpretation, Statistical, Heart Failure, Hospitalization, Humans, Morbidity, Global Health, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
